Fundz

ResMed

United States · Health Care, Medical Device, Mobile

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and ca

Key facts

Headquarters
United States
Employees
10,000
Industries
Health Care, Medical Device, Mobile
Status
Public (RMD)
Website
resmed.com
LinkedIn
Company page

Recent activity at ResMed

  • : SEC 8-K (8.01): On August 31, 2026, ResMed Inc. entered into an accelerated share repurchase agreement (ASR Agreement) with Citibank, N.A. to repurchase $450.0 million worth of its common stock. This action is part of a broader repurchase authorization for 20 million shares approved by the board in February 2014. The funding for this repurchase will come from the proceeds of the recent sale of its MatrixCare business and existing cash reserves. Under the terms of the ASR Agreement, ResMed will pay Citibank $450.0 million on September 3, 2026, in return for an initial delivery of shares representing 80% of the repurchase amount based on the stock's closing price on September 2, 2026. This buyback aligns with the fiscal guidance provided by the company during the Q4 FY26 earnings call on August 6, 2026.
  • : SEC 8-K (5.02):
  • : SEC 8-K (8.01): On August 6, 2026, ResMed Inc. announced a quarterly cash dividend of US $0.66 per share, reflecting a 10% increase from the previous dividend. The key date for shareholders to be on record to receive the dividend is August 20, 2026, with payments scheduled for September 24, 2026. For holders of CHESS Depositary Interests (CDIs) on the Australian Securities Exchange, the dividends will be converted based on the exchange rate on the record date, considering a 10:1 ratio with NYSE shares. Additionally, the ex-dividend date is set for August 19, 2026, and the company has received a waiver from ASX rules to defer processing conversions between stock and CDI registers during a specified period.
  • : SEC 8-K (7.01):
  • : ResMed acquires Noctrix Health for $340 million
  • : ResMed partners with Oura to integrate consumer sleep insights with clinical care pathways.
  • : SEC 8-K (5.02): On April 30, 2026, ResMed Inc. announced that Brett Sandercock will retire from his position as Chief Financial Officer on May 4, 2026. Following his retirement, he will serve as a Special Advisor to Chairman and CEO Mick Farrell until December 31, 2026, with continued salary and benefits. The company appointed Aaron Bloomer as the new Chief Financial Officer, who will start on May 4, 2026, with an annual salary of $725,000 and a sign-on bonus of $150,000. Bloomer, former CFO of Exact Sciences, will also receive a long-term performance equity grant valued at $3,300,000. Sandercock's retirement was amicable and did not involve any disagreements regarding the company’s operations.
  • : SEC 8-K (8.01): On April 30, 2026, ResMed Inc. announced that its board of directors declared a quarterly cash dividend of US $0.60 per share. The dividend has a record date of May 14, 2026, with payment scheduled for June 18, 2026. Holders of common stock listed on the New York Stock Exchange and CHESS Depositary Interests (CDIs) on the Australian Securities Exchange will receive the dividend in their respective currencies. An important aspect of this announcement includes a waiver from the ASX’s settlement operating rules, allowing ResMed to defer processing conversions between its common stock and CDI registers on the record date. This decision can impact shareholder value and market liquidity in both regions.
  • : SEC 8-K (8.01): On January 29, 2026, Resmed Inc. announced a quarterly cash dividend of US $0.60 per share. The record date for this dividend is scheduled for February 12, 2026, and it will be paid on March 19, 2026. The dividend will be distributed in U.S. currency to common stockholders on the New York Stock Exchange, while holders of CHESS Depositary Instruments on the Australian Securities Exchange will receive an equivalent amount in Australian currency. The announcement highlights strategic financial management as part of Resmed's efforts to maintain shareholder value and outlines important timelines, including an ex-dividend date of February 11, 2026.
  • : SEC 8-K (5.02): On November 19, 2025, Richard Sulpizio did not seek re-election at the Annual Meeting, resulting in the expiration of his term and a vacancy on the board of directors, which led to the reduction of the board from twelve to eleven members. During the same meeting, stockholders approved the 2009 Incentive Award Plan Amendment, increasing shares reserved for issuance by 2,400,000 and eliminating the plan's fixed term. Additionally, the stockholders approved the 2018 Employee Stock Purchase Plan Amendment, which increased the share limit by 3,000,000 and eliminated its fixed term. Both plans were amended based on earlier recommendations by the compensation and leadership committee, showing proactive management adjustments to incentivize employee performance.

Leadership

  • VJ, Vice President, Marketing Partnerships & Growth
  • Rishabh Singh, Senior Talent Acquisition Partner
  • Lekha Singh, Senior Talent Acquisition Partner -APAC & EU
  • Aaron Bloomer, Chief Financial Officer
  • Rob Douglas, Chief Operating Officer

Verified email and direct lines for ResMed’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

ResMed files 4 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

ResMed in the news

Companies similar to ResMed

About ResMed: questions and answers

What does ResMed do?

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and ca

Where is ResMed headquartered?

ResMed is headquartered in United States.

How many employees does ResMed have?

ResMed has about 10,000 employees.

Who leads ResMed?

VJ is a Vice President, Marketing Partnerships & Growth at ResMed.

What is the latest news on ResMed?

On Aug 31, 2026, SEC 8-K (8.01): On August 31, 2026, ResMed Inc. entered into an accelerated share repurchase agreement (ASR Agreement) with Citibank, N.A. to repurchase $450.0 million worth of its common stock. This action is part of a broader repurchase authorization for 20 million shares approved by the board in

Is ResMed a public company?

Yes. ResMed is publicly traded under the ticker RMD.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches ResMed across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.